VOLITIONRX LTD
Close on Oct 19, 2026
- Market cap
- $1.59M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $400.00K | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | $1.00M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $600.00K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | $400.00K | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | During market hours | $250.00K | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | $475.00K | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 25, 2024 | During market hours | – | – | – |
Press releases
Announcements Volitionrx filed with the SEC
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
Other events · EX-99.1 to Form 8-K
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Announces Pricing of $4.6 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
Listing notice · Other events · EX-99.1 to Form 8-K
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Listing notice · Other events · EX-99.1 to Form 8-K
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
BRIEF OVERVIEW OF CERTAIN ONCOLOGY ASSETS
Regulation FD disclosure · EX-99.1 to Form 8-K
VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
2024 Mid-Year Review with Cameron Reynolds, Group CEO of Volition
Regulation FD disclosure · EX-99.2 to Form 8-K
VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Volition appoints Dr Andrew Retter as Chief Medical Officer
Other events · EX-99.1 to Form 8-K
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre
Other events · EX-99.1 to Form 8-K
VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Limited Announces Second Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock
Material agreement · Results of operations · Other events · EX-99.3 to Form 8-K
VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K